AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025
Introduction: A New Kind of Biotech Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is redefining drug discovery by combining cutting-edge biology and data science. Based in Salt Lake City, this “TechBio” pioneer uses automation, massive datasets and machine learning to identify new therapies faster than traditional labsdirectorstalkinterviews.comnasdaq.com. Its mission – “to decode biology to radically improve lives” – has attracted major industry partners and bold investors. But as an early-stage biotech with no approved drugs, Recursion’s stock can be a rollercoaster ride, swayed by scientific milestones and market sentiment alike. In early October 2025, Recursion’s stock made headlines after a sudden surge